造血干细胞移植患者人巨细胞病毒临床分离株对更昔洛韦的敏感性测定  

The detection of antiviral susceptibilities of HCMV clinical isolates to ganciclovir from the patients after hematopoietic stem cell transplantation

作　　者：曾爱红[1] 欧阳颖[2] 董德坤[1] 崔喜梅[1] 方建培[2] 

机构地区：[1]中山大学附属第一医院急诊科,广东省广州510080 [2]中山大学附属第二医院儿科

出　　处：《中国基层医药》2013年第3期321-323,共3页Chinese Journal of Primary Medicine and Pharmacy

基　　金：基金项目：广东省科技计划项目（2008B030301080）

摘　　要：目的测定8例造血干细胞移植术后人巨细胞病毒（HCMV）临床分离株对更昔洛韦（GCV）的敏感性，监测该类患者对更昔洛韦的耐药状况。方法收集8例造血干细胞移植术后发生HCMV感染而接受GCV治疗的患者血液或尿液标本，采用HELF细胞培养法分离并鉴定HCMV临床株，50％终点法测定各临床毒株的感染性滴度TCID50,并用MTT法测定各毒株对更昔洛韦的敏感性。结果8株HCMV病毒液的TCID50分别为：10^-4.12／0．1-10^-4.62／0．1ml；8株临床HCMV分离株对更昔洛韦的半数病毒抑制浓度IC卯分别为0．482～1．519mg／L。结论该实验HCMV临床分离株对更昔洛韦敏感性均较高，未发现临床耐药株。Objective To investigate the susceptibilities of HCMV clinical strains isolated to ganciclovir from the patients after hematopoietic stem cell transplantation. Methods Eight HCMV clinical isolates were isolated from the blood or the urine of hematopoietic stem cell transplantation recipients who had been treated with GCV. Tis- sue cell infection median dose（ TCIDso ） were calculated by Reed-Muench method. Drug susceptibility was determined by MTT assay. Results TCIDso values of eight HCMV clinical strains were 10^-4.12/0. lml, 10^-429/0. lml, 10-43/0, lm1,10-44/0, lml 10-442/0. lml, 10-45/0. lml, 10-4＇52/0. lml and 10-4＇62/0. lml respectively. 50% inhibitory concentration（ ICs0 ） to GCV of eight HCMV clinical strains were 0. 638,1. 438,0. 965,0. 698,0. 482, 1. 167,1. 519,1. 511 mg/L respectively. Conclusion Our results suggest that resistant HCMV strains are not preva- lent in Guangzhou. Continuous monitoring of HCMV is needed to understand the antiviral resistance status of the virus in patients after hematopoietic stem cell transplantation and guide its clinical management.

关 键 词：人巨细胞病毒 更昔洛韦 药物敏感性 

分 类 号：R4[医药卫生—临床医学]